Fig. 3: HSPB6 induces apoptosis in prostate cancer.
From: 8-Br-cGMP activates HSPB6 and increases the antineoplastic activity of quinidine in prostate cancer
A HSPB6 expression in different prostate cancer cell lines in the CCLE database. B, C RT-qPCR (B) and Western blot analysis (C) were used to detect the expression of HSPB6 in different prostate cancer cell lines. D, E RT-qPCR (D) and Western blot analysis (E) showed the efficiency of overexpressing HSPB6 in DU145 and C4-2. (P < 0.001 as “***“, P < 0.0001 as “****“, unpaired t test.) F–H Colony formation assays (F, G) and CCK8 (H) showed the proliferation ability of DU145 and C4-2 after overexpression of HSPB6. (P < 0.01 as “**“, P < 0.001 as “***“, unpaired t test, ANOVA.) I–K TUNEL (I) and flow cytometry (J, K) showed the apoptosis levels of DU145 and C4-2 after overexpression of HSPB6. (P < 0.05 as “*“, P < 0.01 as “**“, unpaired t test.) L Mitochondrial membrane potential levels of DU145 and C4-2 after overexpression of HSPB6 were shown by JC-1 staining. M Western blot analysis showed that the expression of the apoptosis marker Cleaved-Caspase-3 after overexpression of HSPB6.
